Corbus

Rachael Brake, PhD, Joins Zephyr AI as Chief Scientific Officer

Retrieved on: 
Tuesday, April 2, 2024
Cardiology, Data Management, Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Software, Artificial Intelligence, Clinical Trials, Translational research, Australian National University, Communication, Corbus, Associate, Takeda Oncology, University, Research, Artificial intelligence, Cancer, Head, Doctor of Philosophy, Molecular biology, Medicine, Biochemistry, Brake, Takeda, Medical research, Interim, Multimedia, Zephyr, Medical device

Zephyr AI, Inc. (“Zephyr AI”), a healthcare technology company committed to developing fast and explainable artificial intelligence (AI) solutions to democratize precision medicine, today announced the appointment of Rachael Brake, PhD, as its new Chief Scientific Officer.

Key Points: 
  • Zephyr AI, Inc. (“Zephyr AI”), a healthcare technology company committed to developing fast and explainable artificial intelligence (AI) solutions to democratize precision medicine, today announced the appointment of Rachael Brake, PhD, as its new Chief Scientific Officer.
  • View the full release here: https://www.businesswire.com/news/home/20240401145891/en/
    “Having spent decades working in big pharma and biotech spanning roles in research, development and commercial, Rachael comes to Zephyr with a unique breadth of experience,” said Jeff Sherman, Zephyr AI Co-Founder, Interim CEO, and Chief Technology Officer.
  • Prior to her work at Corbus, Brake spent 11 years at Takeda Oncology, most recently as Head of U.S. Medical Affairs Oncology.
  • I’m thrilled to be joining the incredibly talented Zephyr AI team at such a pivotal time in clinical research.”

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Retrieved on: 
Friday, February 2, 2024
File, Corbus, Security (finance), Madison Avenue, Telephone, Jefferies, Exercise, Attention, Prospectus, Oppenheimer Holdings, Jefferies Group, Sale

NORWOOD, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the closing of its public offering of 4,973,750 shares of its common stock, including 648,750 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares.

Key Points: 
  • NORWOOD, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the closing of its public offering of 4,973,750 shares of its common stock, including 648,750 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares.
  • All of the common stock was sold at a public offering price of $19.00 per share for a total public offering size of approximately $94.5 million, before deducting underwriting discounts and offering expenses.
  • H.C. Wainwright & Co. and Oppenheimer & Co. acted as lead managers for the offering.
  • The securities described above were offered by Corbus pursuant to a registration statement (File No.

Corbus Pharmaceuticals Announces Pricing of Public Offering

Retrieved on: 
Wednesday, January 31, 2024
Corbus, Madison Avenue, Telephone, Jefferies, Attention, Prospectus, Oppenheimer Holdings, Jefferies Group, Sale, Security (finance)

NORWOOD, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the pricing of an underwritten public offering of 4,325,000 shares of its common stock at a public offering price of $19.00 per share, for a total public offering size of approximately $82.2 million, before deducting underwriting discounts and estimated offering expenses.

Key Points: 
  • NORWOOD, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the pricing of an underwritten public offering of 4,325,000 shares of its common stock at a public offering price of $19.00 per share, for a total public offering size of approximately $82.2 million, before deducting underwriting discounts and estimated offering expenses.
  • All of the securities in the offering are being sold by Corbus.
  • The offering is expected to close on or about February 2, 2024, subject to customary closing conditions.
  • Corbus intends to use the net proceeds of the offering to fund the clinical development of its pipeline and for working capital and other general corporate purposes.

Corbus Pharmaceuticals Announces Proposed Public Offering

Retrieved on: 
Tuesday, January 30, 2024
Corbus, Security (finance), Madison Avenue, Telephone, Jefferies, Attention, Prospectus, Jefferies Group, Sale

All of the securities in the offering are to be sold by Corbus.

Key Points: 
  • All of the securities in the offering are to be sold by Corbus.
  • The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
  • Corbus intends to use the net proceeds of the proposed underwritten offering to fund the clinical development of its pipeline and for working capital and other general corporate purposes.
  • Corbus intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering.

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

Retrieved on: 
Friday, January 26, 2024
MMAE, Neoplasm, Patient, PST, Yale school, CSPC, Shijiazhuang Pharma Group, Yale School of Medicine, ADC, Rash, Peripheral neuropathy, Brentuximab vedotin, ASCO, MUC, Poster, Society, Cervical cancer, Safety, EV, GU, Corbus, Urology, Tab, Trial of the century, Pharmaceutical industry

The poster is titled Phase 1 Dose Escalation of SYS6002(CRB-701), a Next Generation Nectin-4 Targeting Antibody Drug Conjugate by DingWei Ye, et al and is being presented today at the poster session between 11:30 am-1pm PST.

Key Points: 
  • The poster is titled Phase 1 Dose Escalation of SYS6002(CRB-701), a Next Generation Nectin-4 Targeting Antibody Drug Conjugate by DingWei Ye, et al and is being presented today at the poster session between 11:30 am-1pm PST.
  • The poster will also be available on the Corbus website at the start of the poster presentation.
  • We are grateful to CSPC for the work that has gone into conducting this ongoing study and to the clinicians and study participants."
  • Dose escalation and expansion are ongoing and additional data presentations are planned for later this year.

Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023
Rimonabant, NSCLC, Food, Biomarker, Doctor of Philosophy, CB1, Breast cancer, University of Virginia Cancer Center, SITC, The Obesity Society, Head, CSPC, FACP, Human, Therapeutic index, Cleavage, Yale School of Medicine, Society for Immunotherapy of Cancer, Mouse, DIO, Immunotherapy, University, Hand, Investment, Patient, Monoclonal antibody, Food and Drug Administration Amendments Act of 2007, Plasma, Conference, Liraglutide, Development, ADC, Brain, Insulin resistance, Society, AACR, IND, Manuscript, Poster, MMAE, Semaglutide, Tumor microenvironment, Carcinoma, Mab, Neck, Medical imaging, Vaccine, Soft drink, Pharmaceutical industry, Corbus, MD, Obesity

“The third quarter was a productive period for Corbus as data was presented for each of our three programs at relevant scientific conferences” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.

Key Points: 
  • “The third quarter was a productive period for Corbus as data was presented for each of our three programs at relevant scientific conferences” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.
  • Finally, we presented the first ever comprehensive data on CRB-913, our highly peripherally restricted cannabinoid type-1 receptor (CB1) inverse agonist.
  • Early clinical experience will be shared in Q1 2024, which will coincide with the initiation of a U.S./EU trial by Corbus.
  • Corbus presented two posters at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held on November 1 - 5, 2023.

Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023

Retrieved on: 
Tuesday, October 3, 2023
Oncology, Yale School of Medicine, University, CSO, Head, FACP, GU, NSCLC, University of Virginia Cancer Center, Doctor of Philosophy, Biology, ADC, Neck, Breast cancer, Fine chemical, Management, Vaccine, MD, Corbus

The focus for this discussion is on the Nectin-4 targeting ADC (CRB-701) and the diverse indications relevant to its development.

Key Points: 
  • The focus for this discussion is on the Nectin-4 targeting ADC (CRB-701) and the diverse indications relevant to its development.
  • The discussion will define unmet needs, Nectin-4 biology and the features of differentiation in the design of CRB-701 relative to enfortumab vedotin (PADCEV).
  • The panel comprises 3 medical oncologists covering GU, H&N and NSCLC tumors as well as a breast /translational expert.
  • The panel will be moderated by Rachael Brake, PhD, CSO of Corbus.

Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

Retrieved on: 
Wednesday, September 27, 2023
Society, SITC, Immunotherapy, MBA, Biomarker, Doctor of Philosophy, B.S, Poster, Neoplasm, Corbus, IND, Pharmaceutical industry, Vaccine

CRB-601, an integrin αvβ8 blocking antibody entering Phase I: pre-clinical and translational biomarkers for indication selection.

Key Points: 
  • CRB-601, an integrin αvβ8 blocking antibody entering Phase I: pre-clinical and translational biomarkers for indication selection.
  • Vaishali Shinde, Daqing Wang, Danish Memon, Maneesh Singh, James Rindone, Rodney Carter, B.S, Naomi Muse, MBA, Ian Hodgson, PhD, Andrew Kolodziej and Rachael Brake.
  • CRB-601 is a potent and selective integrin αvβ8 blocking monoclonal antibody that can overcome tumor immune exclusion and enhance the activity of immune checkpoint inhibitors in vivo.
  • The CRB-601 abstract will be available on the SITC website as of Oct. 31, 2023, and the poster will be made available on the Company website following the presenation.

Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Tuesday, September 19, 2023
ADC, AACR, Corbus, Conference, MA, Pharmaceutical industry, Fine chemical

NORWOOD, Mass., Sept. 19, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced the pre-clinical data on its CRB-701 Nectin-4 anti-drug-conjugate (ADC) will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, to be held in Boston, MA October 11-15, 2023.

Key Points: 
  • NORWOOD, Mass., Sept. 19, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced the pre-clinical data on its CRB-701 Nectin-4 anti-drug-conjugate (ADC) will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, to be held in Boston, MA October 11-15, 2023.
  • Development of CRB-701 (SYS6002): A novel site-specific, Nectin-4 targeting ADC

Corbus Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

Retrieved on: 
Monday, July 31, 2023
Conference, Cryptocurrency, Consumer electronics, Corbus

NORWOOD, Mass., July 31, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the BTIG Virtual Biotechnology Conference, to be held August 7-8, 2023.

Key Points: 
  • NORWOOD, Mass., July 31, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the BTIG Virtual Biotechnology Conference, to be held August 7-8, 2023.
  • To register for the conference, contact your BTIG sales representative.